Division of Neurology, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.
Women Brain Foundation, Basel, Switzerland.
Nat Aging. 2024 Nov;4(11):1538-1543. doi: 10.1038/s43587-024-00732-x. Epub 2024 Oct 25.
The Clinical Dementia Rating Sum of Boxes (CDR-SB) is a staging scale for Alzheimer's disease (AD) and is commonly used as an outcome in clinical trials. It relies on information provided by the patient and an informant. The CDR-SB should reflect only the patient's disease severity. However, we explored whether informant characteristics were associated with CDR-SB scores because that association might introduce bias in Alzheimer's disease research. We found that the CDR-SB was 0.20 higher when informants were female, 0.39 higher when the informant was a patient's child and 0.18 lower if the relationship was other than spouse or children. Regarding the frequency of contact, CDR-SB scores were 0.38 higher when contact was at least once a week, 0.65 higher when daily and 0.57 higher when living with the patient. Our analysis results suggest that informant characteristics can modify the CDR-SB scores and might introduce bias into Alzheimer's disease trials and research.
临床痴呆评定量表总和分（CDR-SB）是阿尔茨海默病（AD）的分期量表，常用于临床试验的结局指标。它依赖于患者和知情者提供的信息。CDR-SB 应仅反映患者的疾病严重程度。然而，我们探讨了知情者特征是否与 CDR-SB 评分相关，因为这种关联可能会给阿尔茨海默病研究带来偏倚。我们发现，当知情者为女性时，CDR-SB 评分会高 0.20 分；当知情者是患者的子女时，CDR-SB 评分会高 0.39 分；而当关系不是配偶或子女时，CDR-SB 评分会低 0.18 分。关于接触频率，当每周至少接触一次时，CDR-SB 评分会高 0.38 分；当每天接触时，CDR-SB 评分会高 0.65 分；当与患者同住时，CDR-SB 评分会高 0.57 分。我们的分析结果表明，知情者特征可以改变 CDR-SB 评分，并可能给阿尔茨海默病试验和研究带来偏倚。
